Optimal predictors of prostate cancer on repeat prostate biopsy: A prospective study of 1,051 men

Journal of Urology

Volumn 163, Issue 4, 2000, Pages 1144-1149

  Djavan, Bob ^a,b   Zlotta, Alexandre ^a,b   Remzi, Mesut ^a,b   Ghawidel, Keywan ^a,b   Basharkhah, Ali ^a,b   Schulman, Claude C ^a,b   Marberger, Michael ^a,b  

^a UNIVERSITY OF VIENNA   (Austria)

^b ERASME HOSPITAL   (Belgium)

Author keywords

Biopsy; Prostate; Prostate specific antigen; Prostatic hyperplasia; Prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BIOPSY TECHNIQUE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; TREATMENT OUTCOME;

EID: 0034066944     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)67711-7     Document Type: Article

References (33)

1. Cancer Facts and Figures, 1998. Atlanta: American Cancer Society, 1998
2. Partin, A. W. and Oesterling, J. E.: The clinical usefulness of prostate specific antigen: update 1994. J Urol, 152: 1358, 1994
3. Brawer, M. K.: Prostate-specific antigen: critical issues. Urology, 44: 9, 1994
4. Hudson, M. A., Bahnson, R. R. and Catalona, W. J.: Clinical use of prostate specific antigen in patients with prostate cancer. J Urol, 142: 1011, 1989
5. Stamey, T. A., Yang, N., Hay, A. R. et al: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med, 317: 909, 1987
6. Beduschi, M. C. and Oesterling, J. E.: Percent free prostate-specific antigen: the next frontier in prostate-specific antigen testing. Urology, suppl., 51: 98, 1998
7. Catalona, W. J., Smith, D. S., Wolfert, R. L. et al: Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA, 274: 1214, 1995
8. Morote, J., Raventós, C. X., Lorente, J. A. et al: Comparison of percent free prostate specific antigen and prostate specific antigen density as methods to enhance prostate specific antigen specificity in early prostate cancer detection in men with normal rectal examination and prostate specific antigen between 4.1 and 10 ng/mL. J Urol, 158: 502, 1997
9. Vashi, A. R., Wojno, K. J., Henricks, W. et al: Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system. Urology, 49: 19, 1997
10. Bangma, C. H., Rietbergen, J. B. W., Kranse, R. et al: The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population. J Urol, 157: 2191, 1997
11. Bedushi, M. C. and Oesterling, J. E.: Prostate-specific antigen density. Urol Clin North Am, 24: 323, 1997
12. Bazinet, M., Meshref, A. W., Trudel, C. et al: Prospective evaluation of prostate specific antigen density and systematic biopsies for early detection of prostatic carcinoma. Urology, 43: 44, 1994
13. Carter, H. B. and Pearson, J. D.: Prostate-specific antigen velocity and repeated measures of prostate-specific antigen. Urol Clin North Am, 24: 333, 1997
14. Richardson, T. D. and Oesterling, J. E.: Age-specific reference ranges for serum prostate-specific antigen. Urol Clin North Am, 24: 339, 1997
15. Djavan, B., Zlotta, A. R., Byttebier, G. et al: Prostate specific antigen density of the transition zone for early detection of prostate cancer. J Urol, 160: 411, 1998
16. Djavan, B., Zlotta, A., Kratzik, C. et al: PSA, PSA density, PSA density of transition zone, free/total PSA ratio and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/mL. Urology, 54: 517, 1999
17. Djavan, B., Zlotta, A. R., Remzi, M. et al: Total and transition zone prostate volume and age: how do they affect the utility of PSA-based diagnostic parameters for early prostate cancer detection? Urology, 54: 846, 1999
18. Djavan, B., Seitz, C., Remzi, M. et al: Combination and multivariate analysis of PSA-based parameters for prostate cancer prediction. Tech Urol, 5: 71, 1999
19. Zlotta, A. R., Djavan, B., Roumeguère, T. et al: Transition zone volume on transrectal ultrasonography is more accurate and reproducible than the total prostate volume. BJU Int, 84: 661, 1999
20. Catalona, W. J., Partin, A. W., Slawin, K. M. et al: Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA, 279: 1542, 1998
21. Chan, D. W., Sokoll, L. J., Partin, A. W. et al: The use of percent free PSA to predict prostate cancer probabilities: an eleven center prospective study using an automated immunoassay system in a population with non-suspicious DRE. J Urol, suppl., 161: 95, abstract 353, 1999
22. Horninger, W., Reissigl, A., Klocker, H. et al: Improvement of specificity in PSA-based screening by using PSA-transition zone density and percent free PSA in addition to total PSA levels. Prostate, 37: 133, 1998
23. Ukimura, O., Durrani, O. and Babaian, R. J.: Role of PSA and its indices in determining the need for repeat prostate biopsies. Urology, 50: 66, 1997
24. Letran, J. L., Blase, A. B., Loberiza, F. R. et al: Repeat ultrasound guided prostate needle biopsy: use of free-to-total prostate specific antigen ratio in predicting prostatic carcinoma. J Urol, 160: 426, 1998
25. Morgan, T. O., McLeod, D. G., Leifer, E. S. et al: Prospective use of free prostate-specific antigen to avoid repeat prostate biopsies in men with elevated total prostate-specific antigen. Urology, 48: 76, 1996
26. Fleshner, N. E., O'Sullivan, M. and Fair, W. R.: Prevalence and predictors of a positive repeat transrectal ultrasound guided needle biopsy of the prostate. J Urol, 158: 505, 1997
27. Catalona, W. J., Beiser, J. A. and Smith, D. S.: Serum free prostate specific antigen and prostate specific antigen density measurements for predicting cancer in men with prior negative prostatic biopsies. J Urol, 158: 2162, 1997
28. Keetch, D. W., McMurtry, J. M., Smith, D. S. et al: Prostate specific antigen density versus prostate specific antigen slope as predictors of prostate cancer in men with initially negative prostatic biopsies. J Urol, 156: 428, 1996
29. Rietbergen, J. B. W., Boeken Kruger, A. E., Hoedemaeker, R. F. et al: Repeat screening for prostate cancer after 1-year followup in 984 biopsied men: clinical and pathological features of detected cancer. J Urol, 160: 2121, 1998
30. Durkan, G. C. and Greene, D. R.: Elevated serum prostate specific antigen levels in conjunction with an initial prostatic biopsy negative for carcinoma: who should undergo a repeat biopsy? BJU Int, 83: 34, 1999
31. Noguchi, M., Yahara, J., Koga, H. et al: Necessity of repeat biopsies in men for suspected prostate cancer. Int J Urol, 6: 7, 1999
32. Keetch, D. W. and Catalona, W. J.: Prostatic transition zone biopsies in men with previous negative biopsies and persistently elevated serum prostate specific antigen values. J Urol, 154: 1795, 1995
33. Keetch, D. W., Catalona, W. J. and Smith, D. S.: Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J Urol, 151: 1571, 1994